
Key facts
Pethidine 50 50 mg/ml Injection is available on MedEasy for ৳4.94 per 1 ml ampoule, with home delivery anywhere in Bangladesh. It is manufactured by Rephco Pharmaceuticals Ltd. Its generic name is Pethidine Hydrochloride.
- Pack sizes
- 1 ml ampoule
- Prescription
- Required. Upload a valid doctor's prescription at checkout; a MedEasy pharmacist verifies it before dispatch.
- Delivery
- Home delivery across Bangladesh. Same-day delivery (12-24 hours) in Dhaka, Chattogram, Sylhet and Bogura city areas; 1-3 days by courier elsewhere.
- Payment
- Cash on delivery, bKash, cards and mobile banking.
- Brand
- Pethidine 50
- Generic name
- Pethidine Hydrochloride
- Manufacturer
- Rephco Pharmaceuticals Ltd.
- Form & strength
- Injection 50 mg/ml
- Availability
- Currently out of stock
- Authenticity
- Sourced from licensed suppliers and the manufacturer's authorised distributors in Bangladesh.
Medicine overview
Indications of Pethidine 50
Pethidine 50 is an opioid analgesic indicated for the management of moderate-to-severe acute pain where the use of an opioid is appropriate.
- Established/approved use: Short-term management of moderate-to-severe acute pain, including postoperative pain.
- Guideline/traditionally supported use: Labor analgesia (used historically and still used in some settings under obstetric supervision), although other agents are now often preferred.
- Adjunct use: As part of balanced analgesia/anesthesia regimens, and used adjunctively to control post-anesthetic (post-operative) shivering.
Pethidine 50 is not recommended for chronic pain management because repeated dosing can lead to accumulation of a toxic metabolite (normeperidine), which increases the risk of seizures, particularly in patients with renal impairment.
Composition
Each formulation of Pethidine Hydrochloride contains Pethidine Hydrochloride as the active pharmaceutical ingredient. It is commonly available as an injectable solution (e.g., 50 mg/mL or 100 mg/mL) for intramuscular, subcutaneous, or slow intravenous administration; oral tablet formulations exist in some markets but are used less often due to substantial first-pass metabolism and lower oral bioavailability.
Description
Pethidine 50 (meperidine hydrochloride) is a synthetic opioid analgesic belonging to the phenylpiperidine class. It acts primarily as an agonist at mu-opioid receptors in the central nervous system, producing analgesia, sedation, and euphoria similar to morphine, but with a shorter duration of action.
Unique among opioids, Pethidine 50 also has local anesthetic-like (membrane-stabilizing) and atropine-like (anticholinergic) properties, which can produce tachycardia rather than the bradycardia typically seen with other opioids. Its use has declined over recent decades in favor of opioids with more favorable safety profiles, largely because of the risk of accumulation of its neurotoxic metabolite, normeperidine.
Therapeutic Class
Pethidine 50 belongs to the therapeutic class of Opioid Analgesics (phenylpiperidine derivatives), used for the relief of moderate-to-severe acute pain.
Pharmacology
Pethidine Hydrochloride exerts its analgesic effect chiefly through agonist activity at mu-opioid receptors distributed throughout the central nervous system and periphery, mimicking the action of endogenous opioid peptides (enkephalins/endorphins). This reduces neuronal excitability and inhibits ascending pain transmission pathways, altering both the perception of and the emotional response to pain.
In addition to opioid-receptor agonism, Pethidine Hydrochloride has weak local anesthetic (sodium channel-blocking) activity and anticholinergic (atropine-like) effects, which explain findings such as tachycardia and dry mouth that differ from typical opioid effects.
Pethidine Hydrochloride is metabolized in the liver, chiefly by hydrolysis to meperidinic acid and by N-demethylation to normeperidine, an active metabolite with weaker analgesic activity but significant CNS-excitatory/proconvulsant potential. Normeperidine has a longer elimination half-life than the parent drug and accumulates with repeated dosing or in renal impairment, increasing seizure risk. Metabolites are excreted renally.
Dosage & Administration of Pethidine 50
Adults
| Indication | Route | Typical Dose |
|---|---|---|
| Moderate-to-severe acute pain | IM or SC | 50–150 mg every 3–4 hours as needed |
| Moderate-to-severe acute pain | Slow IV (diluted) | 25–100 mg, titrated slowly, with monitoring |
| Labor analgesia (under obstetric supervision) | IM or SC | 50–100 mg, repeated at 1–3 hour intervals as directed |
Pediatric Patients
1.0–1.8 mg/kg by IM, SC, or slow IV injection every 3–4 hours as needed, not to exceed the usual adult dose. Safety and efficacy in neonates have not been established, and use in this age group is generally avoided (see Use in Special Populations).
Renal/Hepatic Impairment
Use is generally avoided or requires substantial dose reduction and extended dosing intervals with close monitoring, because reduced clearance of the toxic metabolite normeperidine increases the risk of CNS excitation and seizures (see Precautions and Warnings).
Duration
Treatment with Pethidine 50 should be limited to the shortest duration consistent with the treatment goal, generally not more than a few days, due to the risk of metabolite accumulation and dependence.
Administration of Pethidine 50
Pethidine 50 may be given by intramuscular (IM), subcutaneous (SC), or slow intravenous (IV) injection; oral administration is uncommon due to low bioavailability. IV doses must be given slowly and diluted, with the patient in a recumbent position and vital signs monitored, since rapid IV administration increases the risk of hypotension and respiratory depression. Resuscitative equipment and an opioid antagonist (naloxone) should be available whenever Pethidine 50 is administered parenterally.
Interaction of Pethidine 50
Pethidine 50 has several clinically significant drug interactions:
- Monoamine oxidase inhibitors (MAOIs): Concurrent use, or use within 14 days of an MAOI, can precipitate severe, unpredictable, and potentially fatal reactions, including serotonin syndrome and excitatory or depressive CNS crises. This combination is contraindicated (see Contraindications).
- Other CNS depressants (benzodiazepines, other opioids, sedative-hypnotics, alcohol, general anesthetics): Additive sedation, respiratory depression, hypotension, and coma; concomitant use requires dose reduction and close monitoring.
- Serotonergic drugs (SSRIs, SNRIs, triptans, other serotonergic agents): Increased risk of serotonin syndrome.
- Phenytoin and other enzyme inducers/CYP substrates: May increase formation of the toxic metabolite normeperidine, raising seizure risk.
- Anticholinergic drugs: May potentiate the anticholinergic (atropine-like) effects of Pethidine 50, such as dry mouth, urinary retention, and constipation.
Contraindications
Pethidine Hydrochloride is contraindicated in:
- Patients with known hypersensitivity to Pethidine Hydrochloride or to any other opioid of the phenylpiperidine class.
- Patients who have received monoamine oxidase inhibitors (MAOIs) within the preceding 14 days, due to the risk of severe, potentially fatal serotonin syndrome or excitatory/depressive reactions.
- Significant respiratory depression, particularly in unmonitored settings or in the absence of resuscitative equipment.
- Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment.
- Known or suspected gastrointestinal obstruction, including paralytic ileus.
Side Effects of Pethidine 50
Common and serious adverse effects associated with Pethidine 50 include:
- Common: Sedation, dizziness, lightheadedness, nausea, vomiting, constipation, dry mouth, sweating.
- Cardiovascular: Tachycardia (due to the drug's atropine-like effect, unlike the bradycardia seen with most other opioids), hypotension (especially with rapid IV administration or in ambulatory patients), syncope.
- Respiratory: Dose-dependent respiratory depression, which can be severe or fatal, especially when combined with other CNS depressants.
- Neurological: Seizures, tremor, muscle twitching, and agitation, particularly with high-dose or prolonged use due to normeperidine accumulation.
- Other: Physical dependence and tolerance with repeated use; urinary retention; pruritus/rash.
Pregnancy & Lactation
Pethidine 50 crosses the placenta. Use during pregnancy, especially near term or during labor, may cause neonatal respiratory depression, and prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome. Pethidine 50 should be used during pregnancy only if clearly needed and only under obstetric/medical supervision, with the potential benefit weighed against potential risk to the fetus/neonate.
Pethidine 50 and its metabolites are excreted in breast milk. Breastfeeding is generally not recommended during and immediately after use, and if used, the infant should be monitored for sedation, poor feeding, or respiratory difficulty. Consult a physician before use during breastfeeding.
Precautions & Warnings
Pethidine 50 carries important warnings common to opioid analgesics:
- Addiction, abuse, and misuse: Pethidine 50 exposes patients to the risk of opioid addiction, abuse, and misuse, which can lead to overdose and death; it is a controlled substance.
- Life-threatening respiratory depression: Risk is greatest during initiation of therapy or after a dose increase, and is increased with concomitant use of other CNS depressants (see Interactions).
- Normeperidine accumulation/seizures: Repeated or high-dose use, especially in patients with renal impairment, can lead to accumulation of the toxic metabolite normeperidine, causing CNS excitation and seizures; Pethidine 50 is generally not recommended for chronic pain management.
- Neonatal opioid withdrawal syndrome: Prolonged use during pregnancy can result in withdrawal in the newborn (see Pregnancy and Lactation).
- Use with caution in: Head injury or raised intracranial pressure (may obscure clinical course and increase carbon dioxide retention), biliary tract disease/pancreatitis (may cause spasm of the sphincter of Oddi), seizure disorders, hepatic or renal impairment, elderly or debilitated patients, and patients with respiratory disease (e.g., COPD, cor pulmonale).
Overdose Effects of Pethidine 50
Overdose with Pethidine 50 is a medical emergency. Features may include marked respiratory depression, extreme drowsiness progressing to stupor or coma, muscle flaccidity, cold and clammy skin, miosis or, in severe hypoxia or with seizures, mydriasis, bradycardia, hypotension, and seizures (related to accumulation of normeperidine).
If overdose is suspected, seek immediate emergency medical attention or contact a poison control center. Treatment is supportive and must be provided in a healthcare setting; it may include airway support, ventilatory assistance, and administration of an opioid antagonist (naloxone) for respiratory depression, with awareness that naloxone may not reliably reverse normeperidine-induced seizures and that seizure activity may need separate management. Do not attempt to manage a suspected overdose at home.
Storage Conditions
Store at room temperature (below 30°C), away from light and moisture. Do not freeze injectable solutions. Keep out of reach of children.
Use In Special Populations
Elderly: Increased sensitivity to the respiratory depressant and sedative effects of Pethidine 50; start at a lower dose with careful monitoring.
Renal impairment: Use is generally avoided or requires marked dose reduction, as reduced clearance of normeperidine increases seizure risk (see Precautions and Warnings).
Hepatic impairment: Reduced drug clearance; use with caution and reduced dosing.
Pediatric patients: Weight-based dosing may be used for acute pain in children (see Dosage and Administration), but safety and efficacy have not been established in neonates, and use in this group is generally avoided due to heightened risk of respiratory depression.
Duration Of Treatment
Pethidine 50 is intended for short-term use only, generally limited to the treatment of acute pain for the shortest duration consistent with the patient's needs, typically no more than a few days. It is not recommended for repeated or long-term dosing because of the risk of normeperidine accumulation, seizures, and the development of tolerance and dependence.
Drug Classes
Pethidine Hydrochloride is classified as an Opioid Analgesic, specifically a phenylpiperidine-derivative opioid, and is a controlled substance due to its potential for abuse and dependence.
Mode Of Action
Pethidine Hydrochloride acts as an agonist at mu-opioid receptors in the central nervous system and periphery, mimicking endogenous opioid peptides to inhibit ascending pain transmission and alter the perception of and emotional response to pain. It additionally has weak local anesthetic (sodium channel-blocking) and anticholinergic (atropine-like) activity, which distinguish some of its clinical effects from other opioids.
Pregnancy
C
Pediatric Uses
Pethidine 50 may be used cautiously in children for the short-term management of acute pain, at a weight-based dose (approximately 1.0–1.8 mg/kg by IM, SC, or slow IV injection every 3–4 hours as needed), not exceeding the usual adult dose. Safety and efficacy in neonates have not been established, and Pethidine 50 is generally not used in this age group because of an increased risk of respiratory depression. Pediatric patients should be closely monitored for sedation and respiratory status during treatment.
Frequently Asked Questions
Q: What is Pethidine 50 50 mg/ml Injection used for?
A: Pethidine 50 50 mg/ml Injection is an opioid analgesic used for the short-term management of moderate-to-severe acute pain, such as postoperative pain, and historically for labor pain under medical supervision.
Q: Can Pethidine 50 50 mg/ml Injection be used for long-term or chronic pain?
A: No. Pethidine 50 50 mg/ml Injection is not recommended for chronic pain because repeated or prolonged dosing can cause accumulation of a toxic metabolite (normeperidine) that increases the risk of seizures, especially in people with kidney problems.
Q: Who should not take Pethidine 50 50 mg/ml Injection?
A: Pethidine 50 50 mg/ml Injection should not be used by anyone with a known hypersensitivity to it, by anyone who has taken a monoamine oxidase inhibitor (MAOI) within the past 14 days (risk of severe, potentially fatal reactions), by patients with significant, unmonitored respiratory depression, by patients with acute or severe asthma in an unmonitored setting, or by patients with known or suspected bowel obstruction.
Q: Is Pethidine 50 50 mg/ml Injection safe during pregnancy or breastfeeding?
A: Pethidine 50 50 mg/ml Injection should be used in pregnancy only if clearly needed and under medical/obstetric supervision, since use near delivery can cause breathing problems or withdrawal symptoms in the newborn. It passes into breast milk, so breastfeeding is generally discouraged during use; consult a physician for guidance.
Q: What are the main side effects of Pethidine 50 50 mg/ml Injection?
A: Common side effects include drowsiness, dizziness, nausea, vomiting, constipation, dry mouth, and sweating. More serious risks include slowed or stopped breathing, a fast heart rate, low blood pressure, and seizures, particularly with high doses or repeated use.
Q: What should I do if too much Pethidine 50 50 mg/ml Injection is taken?
A: Overdose with Pethidine 50 50 mg/ml Injection is a medical emergency. Seek immediate emergency medical attention or contact a poison control center right away; do not try to manage an overdose at home.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.